In vitro antibiotic sensitivity testing breakpoints and therapeutic activity in induced infections in animal models

Journal of Chemotherapy

Volumn 9, Issue SUPPL. 1, 1997, Pages 36-46

  Soriano, F ^a   Aguilar, L ^b   Ponte, C ^a  

^a Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^b SmithKline Beecham   (Spain)

Author keywords

Animal models; Inoculum; Quinolones; Susceptibility testing; Toxicity

Indexed keywords

AMINOGLYCOSIDE; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AZTREONAM; CEFALOTIN; CEFMETAZOLE; CEFOXITIN; CEFTAZIDIME; CEFTIZOXIME; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLINDAMYCIN; ERYTHROMYCIN; GENTAMICIN; MACROLIDE; METRONIDAZOLE; MEZLOCILLIN; OXACILLIN; PEFLOXACIN; PENICILLIN DERIVATIVE; PIPERACILLIN; QUINOLONE DERIVATIVE; SISOMICIN; SULBACTAM; TEICOPLANIN; TICARCILLIN; UNINDEXED DRUG; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; CONFERENCE PAPER; DRUG EFFICACY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; RABBIT; RAT; RESPIRATORY TRACT INFECTION;

ANIMALS; BACTERIAL INFECTIONS; DISEASE MODELS, ANIMAL; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 0030741267     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (60)

1. Verbist L. Relevance of antibiotic susceptibility testing tor clinical practice. Eur J Clin Microbiol Infect Dis 1993; 12 (suppl. 1): 2-5.
2. Williams JD. BSAC guidelines on sensitivity testing. J Antimicrob Chemother 1993; 31: 1001-1003.
3. Beam TR Jr, Gilbert DN, Kunin CM. General guidelines for the clinical evaluation of anti-infective drug products. Clin Infect Dis 1992; 15 (suppl. 1): 5-32.
4. Hindler JA, Thrupp LD. Interpretative guidelines for antimicrobial susceptibility results: what do they mean. Clin Microbiol Newsl 1989; 11: 129-134.
5. Report of the Working PaMy on Antibiotic Sensitivity Testing of the British Society for Antimicrobial Chemotherapy. A guide to sensitivity testing. J Antimicrob Chemother 1991; 27 (suppl.D): 1-50.
6. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. Sixth informational supplement. 1995; vol 15, no 14, M100-S6. Villanova, PA.
7. Sánchez C, Armengol R, Lite I, Mir I, Garau J. Penicillin resistant pneumococci and community-acquired pneumonia. Lancet 1992; 339: 988.
8. Pallarés R, Liñares J, Vadillo M, et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 1995; 333: 474-480.
9. Kayser FH, Morenzoni G, Santanam P. The second European collaborative study on the frequency of antimicrobial resistance in Haemophilus influenzae. Eur J Clin Microbiol Infect Dis 1990; 9: 810-817.
10. Brun Y, Forey F, Gamondes JP, Tebib A, Brune J, Fleurette J. Levels of erythromycin in pulmonary tissue and bronchial mucus compared to those of amoxycillin. J Antimicrob Chemother 1981; 8: 459-466.
11. Ginsburg CM, Lichenwald HF. Erythromycin: a review of its uses in pediatric practice. J Pediatr 1976; 89: 872-884.
12. Greenwood D. In vitro veritas? Antimicrobial susceptibility tests and their clinical relevance. J Infect Dis 1981; 144: 380-385.
13. Craig W. Relevance of animal models for clinical treat ment. Eur J Clin Microbiol Infect Dis 1993; 12 (suppl.1) : 55-57.
14. Gootz TD. Discovery and development of new antimicrobial agents. Clin Microbiol Rev 1990; 3: 13-31.
15. Zak O, O'Reilly T. Animal models in the evaluation of antimicrobial agents. Antimicrob Agents Chemother 1991; 35: 1527-1531.
16. Carbon C. Significance of tissue levels for prediction of antibiotic efficacy and determination of dosage. Eur J Clin Microbiol Infect Dis 1990; 9: 510-516.
17. Vogelman B, Gudmundsson S, Leggett J, Turnidge J, Ebert S, Craig WA. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis 1988; 158: 831-847.
18. Leggett JE, Fantin B, Ebert S, et al. Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models. J Infect Dis 1989; 159: 281-292.
19. Joiner K, Lowe B, Dzink J, Bartlett JG. Comparative efficacy of 10 antimicrobial agents in experimental infections with Bacteroides fragilis. J Infect Dis 1982; 145: 561-568.
20. Report of a Working Party of the British Society of Antimicrobial Chemotherapy. The clinical evaluation of antibacterial drugs. J Antimicrob Chemother 1989; 23(suppl.B): 1-42.
21. Thrupp LD, Cleeland R, Jones RN, Novick WJ Jr, Reller LB, Thornsberry CL, Washington JA. General guidelines for clinical bacteriology. Clin Infect Dis 1992; 15(suppl. 1): 339-346.
22. Soriano F, García-Corbeira P, Ponte C, Fernández-Roblas R, Gadea I. Correlation of pharmacodynamic parameters of five ß-lactam antibiotics with therapeutic efficacies in an animal model. Antimicrob Agents Chemother 1996; 40: 2686-2690.
23. Backes RJ, Rouse MS, Henry NK, Geraci JE, Wilson WR. Activity of penicillin combined with an aminoglycoside against group B streptococci in vitro and in experimental endocarditis. J Antimicrob Chemother 1986; 18: 491-498.
24. Azoulay-Dupuis E, Vallee E, Veber B, Bedos JP, Bauchet J, Pocidalo JJ. In vivo efficacy of a new fluoroquinolone, sparfloxacin, against penicillin-susceptible and - resistant and multiresistant strains of Streptococcus pneumoniae in a mouse model of pneumonia. Antimicrob Agents Chemother 1992; 36: 2698-2703.
25. Sullivan MC, Cooper BW, Nightingale CH, Quintiliani R, Lawlor MT. Evaluation of the efficacy of ciprofloxacin against Streptococcus pneumoniae by using a mouse protection model. Antimicrob Agents Chemothcr 1993; 37: 234-239.
26. Gisby J, Wightman BJ, Beale AS. Comparative efficacies of ciprofloxacin, amoxicillin, amoxicillin-clavulanic acid, and cefaclor against experimental Streptococcus pneumoniae respiratory infections in mice. Antimicrob Agents Chemother 1991; 35: 831-836.
27. Moine P, Vallée É, Azoulay-Dupuis E, Bourget P, Bédos JP, Bauchet J, Pocidalo JJ. In vivo efficacy of a broadspectrum cephalosporin, ceftriaxone, against penicillin-susceptible and -resistant strains of Streptococcus pneumoniae in a mouse pneumonia model. Antimicrob Agents Chemother 1994; 38: 1953-1958.
28. Fernández-Guerrero ML, Arbol F, Verdejo C, Fernández-Roblas R, Soriano F. Treatment of experimental endocarditis due to penicillin-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother 1994; 38: 1103-1106.
29. Paris MM, Mickey SM, Uscher MI, Shelton S, Olsen KD, McCracken GH Jr. Effect of dexamethasone on therapy of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother 1994; 38:1320-1324.
30. Soriano F, Rodríguez-Tudela JL, Castilla C, Avilés P. Treatment of encrusted cystitis caused by Corynebacterium group D2 with norfloxacin, ciprofloxacin and teicoplanin in an experimental model in rats. Antimicrob Agents Chemother 1991; 35: 2587-2590.
31. Ponte C, Parra A, Nieto E, Soriano F. Development of experimental pneumonia by infection with penicillin-insensitive Streptococcus pneumoniae in guinea pigs and their treatment with amoxicillin, cefotaxime, and meropenem. Antimicrob Agents Chemother 1996; 40: 2698-2702.
32. Fantin B, Carbon C. In vivo antibiotic synergism: contribution of animal models. Antimicrob Agents Chemother 1992; 36: 907-912.
33. Soriano F, Ponte C, Gaspar MC. Reciprocal antimicrobial synergism between Escherichia coli and Racteroides fragilis in the presence of metronidazole. J Clin Pathol 1982; 35: 1150-1152.
34. Boon RJ, Beale AS. Response of Streptococcus pyogenes to therapy with amoxicillin or amoxicillin-clavulanic acid in a mouse model of mixed infection caused by Staphylococcus aureus and Streptococcus pyogenes. Antimicrob Agents Chemother 1987; 31: 1204-1209.
35. Soriano F, Ponte C, Santamaría M, Castilla C. Effect of Bacteroides fragilis on mortality induced by Escherichia coli in an experimental infection treated with cefotaxime, aztreonam or gentamicin. J Antimicrob Chemother 1989; 23: 383-388.
36. Brook I. The concept of indirect pathogenicity by ß-lactamase production, especially in ear, nose and throat infection. J Antimicrob Chemother 1989; 24 (suppl.B): 63-72.
37. Quintiliani R, Nightingale CH. Strategic antibiotic decision-making at the formulary level. Rev Infect Dis 1991; 13 (suppl. 9): 770-772.
38. Soriano F, Santamaría M, Ponte C, Castilla C, Fernández-Roblas R. In vivo significance of the inoculum effect of antibiotic on Escherichia coli. Eur J Clin Microbiol Infect Dis 1988; 7: 410-412.
39. Soriano F, Ponte C, Santamaria M, Jiménez M. Relevance of the inoculum effect of antibiotics in the outcome of experimental infections caused by Escbericbia coli. J Antimicrob Chemother 1990; 25: 621-627.
40. Soriano F. Optimal dosage of ß-lactam antibiotics. Time over MIC and inoculum effect (leading article). J Antimicrob Chemother 1992; 30: 566-569.
41. Soriano F, Edwards R, Greenwood D. Effect of inoculum size on the bacteriolytic activity of cefminox and four other ß-lactam antibiotics against Escherichia coli. Antimicrob Agents Chemother 1992; 36: 223-226.
42. Onyeji CO, Nicolau DP, Nightingale CH, Quintiliani R. Optimal times above MICs of ceftibuten and cefaclor in experimental intra-abdominal infections. Antimicrob Agents Chemother 1994; 38: 1112-1117.
43. König C, Simmen HP, Blaser J. High numbers of cfu at onset of therapy compared to inoculum size of in vitro susceptibility tests and implications on bactericidal activity. Abstracts 36th ICAAC. New Orleans, 1996: 67.
44. Goldstein EJ, Citron DM, Cherubin CE. Comparison of the inoculum effects of members of the family Enterobacteriaceae on cefoxitin and other cephalosporins, ß-lactamase inhibitor combinations, and the penicillin-derived components of these combinations. Antimicrob Agents Chemother 1991; 35: 560-566.
45. Goldstein EJ, Citron DM, Cherubin CE. Comparison of the inoculum effect of cefoxitin and other cephalosporins and of ß-lactamase inhibitors and their penicillin-derived components on the Bacteroides fragilis group. Antimicrob Agents Chemother 1991; 35: 1868-1874.
46. Brook I. In-vitro sensitivity tests and in-vivo efficacy of cephalosporins against Bacteroides fragilis. J Antimicrob Chemother 1990; 26: 158-161.
47. Gerding DN, Peterson LR, Moody JA, Fashing CE. Mezlocillin, ceftizoxime, and amikacin alone and in combination against six Enterobacteriaceae in a neutropenic site in rabbits. J Amtimicrob Chemother 1985; 15 (suppl. A): 207-219.
48. Davies BI, Maesen FP, Baur C. Ciprofloxacin in the treatment of chronic bronchitis. Eur J Microbiol 1986; 5: 226-231.
49. Cooper B, Lawlor M. Pneumococcal bacteremia during ciprofloxacin therapy for pneumococcal pneumonia. Am J Med 1989; 87:475.
50. Frieden TR, Mangi RJ. Inappropriate use of oral ciprofloxacin. JAMA 1990; 264: 1438-1440.
51. Appelbaum PC. Antimicrobial resistance in Streptococcus pneumoniae: an overview. Clin Infect Dis 1992; 15: 77-83.
52. Andes D, Urban A, Craig WA. In-vivo activity of amoxicillin (amox) and amoxicillin/clavulanate (amox/clav) against penicillin-resistant pneumococci. Abstract 35th ICAAC, San Francisco, 1995.
53. Soriano F, Ponte C, Nieto F, Parra A. Correlation of in-vitro activity and pharmacokinetic parameters with in-vivo effect of amoxycillin, co-amoxiclav and cefotaxime in a murine model of pneumococcal pneumonia. J Antimicrob Chemother 1996; 38: 227-236.
54. National Committeee for Clinical Laboratory Standards. Methods of dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A3. 3rd ed. National Committee for Clinical Laboratory Standards, Villanova, Pa 1993.
55. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A2. 2nd ed. National Committee for Clinical Laboratory Standards Villanova, Pa. 1990.
56. Sloas MM, Barrett FF, Chesney PJ, English BK, Hill BC, Tenover FC, Leggiadro RJ. Cephalosporin treatment failure in penicillin- and cephalosporin-resistant Streptococcus pneumonias meningitis. Pediatr Infect Dis J 1992; 11: 662-666.
57. Friedland IR, McCracken Jr GH. Management of infections caused by antibiotic-resistant Streptococcus pneumoniae. N Engl J Med 1994; 331: 377-382.
58. Jacobs RF, Kaplan SL, Schutze GH, Dajani AS, Leggiadro RJ, Rim C-S, Puri SK. Relationship of MICs to efficacy of cefotaxime in treatment of Streptococcus pneumoniae infection. Antimicrob Agents Chemother 1996; 40: 895-898.
59. Viladrich PF, Cabellos C, Pallares R, Tubau F, Martínez-Lacasa J, Liñares J, Gudiol F. High doses of cefotaxime in treatment ot adult meningitis due to Streptococcus pneumoniae with decreased susceptibilities to broad-spectrum cephalosporins. Antimicrob Agents Chemother 1996; 40: 218-220.
60. Craig W. Experimental data as a basis ot breakpoints. Abstracts 7th International Congress for Infectious Diseases. Hong Kong, 1996: 205.